

Pharmacy and Therapeutics Committee Virtual Meeting

January 19, 2022

12:00 PM - 5:00 PM

Zoom Meeting Registration:

To attend the meeting from a PC, Mac, iPad, iPhone, or Android device, please click on the URL below:

https://ahcccs.zoom.us/webinar/register/WN__7swQ37yT7y1-PKzB1_U1g

Time	Topic
12:00 PM	<p>Welcome and Introductions: Suzanne Berman, RPH, AHCCCS Pharmacy Director</p> <p>P&T October 18, 2021 - Minutes Review and Vote</p>
12:15 PM	<p>One Supplemental Rebate and Eighteen Non-Supplemental Rebate Class Reviews: Clinical review by Sarah Martinez, PharmD, Magellan</p> <ol style="list-style-type: none"> 1. Androgenic Agents <ol style="list-style-type: none"> a. Public Testimony: None 2. Antidepressants, Others <ol style="list-style-type: none"> a. Public Testimony: Written testimony received from <ol style="list-style-type: none"> i. Jasleen Chhatwal MD on behalf of the Arizona Psychiatric Society ii. Chiranjir Narine MD on behalf of District Medical Group 3. Antidepressants, SSRIs <ol style="list-style-type: none"> a. Public Testimony: None 4. Antivirals - Topical <ol style="list-style-type: none"> a. Public Testimony: None 5. Bone Resorption Suppression Agents <ol style="list-style-type: none"> a. Public Testimony: None 6. Bronchodilators, Beta Agonists <ol style="list-style-type: none"> a. Public Testimony: None 7. Colony Stimulating Factors <ol style="list-style-type: none"> a. Public Testimony: None 8. Enzyme Replacement, Gaucher Disease <ol style="list-style-type: none"> a. Public Testimony: None 9. Erythropoiesis Stimulating Proteins <ol style="list-style-type: none"> a. Public Testimony: None 10. Hypoglycemics, Alpha-Glucosidase Inhibitors <ol style="list-style-type: none"> a. Public Testimony: None

	<p>11. Hypoglycemics, Metformins a. Public Testimony: None</p> <p>12. Hypoglycemics, SGLT2s a. Public Testimony: None</p> <p>13. Immune Globulins a. Public Testimony: None</p> <p>14. Oral Oncology, Oral, Hematologic - Brand/Generic a. Public Testimony: i. Brukinsa written testimony received from Marjan Massoudi on behalf of Beigene</p> <p>15. Ophthalmics, Anti-Inflammatory Products a. Public Testimony: None</p> <p>16. Otic Antibiotics a. Public Testimony: None</p> <p>17. Pulmonary Atrial Hypertension (PAH) Agents a. Public Testimony: i. Tyvaso written testimony received from Peter Barrio on behalf of United Therapeutics</p> <p>18. Thrombopoiesis Stimulating Proteins a. Public Testimony: None</p> <p>19. Ulcerative Colitis Agents a. Public Testimony: None</p>																																							
<p>1:50 PM</p>	<p>New Drug Reviews: Sarah Martinez, PharmD, Magellan</p> <table border="1" data-bbox="256 1192 1528 1734"> <thead> <tr> <th><i>Brand Name</i></th> <th><i>Generic Name</i></th> <th><i>Drug Class</i></th> </tr> </thead> <tbody> <tr> <td>Azstarys</td> <td>Serdexmethylphenidate & Dexmethylphenidate</td> <td>Stimulants</td> </tr> <tr> <td>Bylvay</td> <td>Odevixibat</td> <td>Bile Salts</td> </tr> <tr> <td>Kerendia</td> <td>Finerenone</td> <td>Diuretics</td> </tr> <tr> <td>Livmarli</td> <td>Maralixibat</td> <td>Bile Sales</td> </tr> <tr> <td>Livtency</td> <td>Maribavir</td> <td>Antivirals, General</td> </tr> <tr> <td>Lybalvi</td> <td>Olanzapine & Samidorphan</td> <td>Antipsychotics</td> </tr> <tr> <td>Opzelura</td> <td>Ruxolitinib</td> <td>Immunomodulators, Atopic Dermatitis</td> </tr> <tr> <td>Qulipta</td> <td>Atogepant</td> <td>Antimigraine Agents</td> </tr> <tr> <td>Rezurock</td> <td>Belumosudil</td> <td>Cytokine & CAM Antagonists</td> </tr> <tr> <td>Skytrofa</td> <td>Lonapegsomatropin</td> <td>Growth Hormone</td> </tr> <tr> <td>Tavneos</td> <td>Avacopan</td> <td>Complement Inhibitor</td> </tr> <tr> <td>Tryvaya Spray</td> <td>Verenicline</td> <td>Ophthalmics, Anti-inflammatory /Immunomodulators</td> </tr> </tbody> </table>	<i>Brand Name</i>	<i>Generic Name</i>	<i>Drug Class</i>	Azstarys	Serdexmethylphenidate & Dexmethylphenidate	Stimulants	Bylvay	Odevixibat	Bile Salts	Kerendia	Finerenone	Diuretics	Livmarli	Maralixibat	Bile Sales	Livtency	Maribavir	Antivirals, General	Lybalvi	Olanzapine & Samidorphan	Antipsychotics	Opzelura	Ruxolitinib	Immunomodulators, Atopic Dermatitis	Qulipta	Atogepant	Antimigraine Agents	Rezurock	Belumosudil	Cytokine & CAM Antagonists	Skytrofa	Lonapegsomatropin	Growth Hormone	Tavneos	Avacopan	Complement Inhibitor	Tryvaya Spray	Verenicline	Ophthalmics, Anti-inflammatory /Immunomodulators
<i>Brand Name</i>	<i>Generic Name</i>	<i>Drug Class</i>																																						
Azstarys	Serdexmethylphenidate & Dexmethylphenidate	Stimulants																																						
Bylvay	Odevixibat	Bile Salts																																						
Kerendia	Finerenone	Diuretics																																						
Livmarli	Maralixibat	Bile Sales																																						
Livtency	Maribavir	Antivirals, General																																						
Lybalvi	Olanzapine & Samidorphan	Antipsychotics																																						
Opzelura	Ruxolitinib	Immunomodulators, Atopic Dermatitis																																						
Qulipta	Atogepant	Antimigraine Agents																																						
Rezurock	Belumosudil	Cytokine & CAM Antagonists																																						
Skytrofa	Lonapegsomatropin	Growth Hormone																																						
Tavneos	Avacopan	Complement Inhibitor																																						
Tryvaya Spray	Verenicline	Ophthalmics, Anti-inflammatory /Immunomodulators																																						
<p>2:15 PM</p>	<p>Break & Executive Session – Kristen Haloski, PharmD, AAHIVP, Magellan</p>																																							
<p>4:15 PM</p>	<p>Public Therapeutic Class Votes – Sarah Martinez, PharmD, Magellan</p>																																							
<p>4:45 PM</p>	<p>Biosimilar Update: None</p>																																							
<p>4:45 PM</p>	<p>Meeting Adjournment Future Meeting Dates: May 24, 2022, October 19, 2022</p>																																							